Home
  >  
Section 7
  >  
Chapter 6,848

Tumor-specific immunity induced by somatic hybrids. II. Elicitation of enhanced immunity against the parent plasmacytoma

Kim, B.S.

Journal of Immunology 123(2): 739-744

1979


ISSN/ISBN: 0022-1767
PMID: 88483
Accession: 006847517

Hybrid cells derived from fusion of a BALB/c plasmacytoma (TEPC-15) and L [mouse neoplastic fibroblast] cells (C3H origin) were used to stimulate tumor-specific immunity against the parental plasmacytoma cells. Live hybrid cells induced tumor-specific immunity against TEPC-15 more effectively than mitomycin-treated hybrid or TEPC-15 tumor cells. Adoptive transfer of immunity with spleen cells of mice immunized with hybrid cells was more effective than that with mitomycin-treated tumor cells. The immunity induced by the hybrid cells was specific to the TEPC-15 tumor because the mice that received immune spleen cells were not protected against challenge with HOPC-8 or McPC-603 plasmacytomas. T [thymus-derived] cell populations were primarily responsible for the transfer of specific immunity based on the sensitivity of immune cells to anti-Thy 1.2 and complement. Mice that had established solid tumors were treated with 5 .times. 107 spleen cells to evaluate the therapeutic value of the hybrid-induced immune cells. Tumors in the mice that received immune cells gradually regressed over a 40-day period whereas tumors on the control mice continued to grow. A rearrangement of tumor-specific antigens on allogeneic hybrid cells may enhance their immunogenicity.

PDF emailed within 1 workday: $29.90